Tadashi Manabe MD, PhD
@Tadashi_Manabe
Postdoc @UCSF, @BivonaLabUCSF 2021.4-. Board-certified respiratory physician specializing in lung cancer. @DamonRunyon Fellow. MD ＆ PhD from Keio Univ., Japan.
It was great to connect with my Japanese colleague on the final day of #AACR25 ! Exciting to exchange ideas on our complementary approaches to tackling NSCLC! @toshio_fujino
Successfully presented my research on Exarafenib at #AACR25 today. Grateful to the session chairs for their valuable feedback and support. Looking forward to the future of BRAF-targeted therapies in cancer! #CancerResearch #LungCancer #BRAF
Excited to present my research on Exarafenib at #AACR25 tomorrow. My work demonstrates promising efficacy against all classes of BRAF mutations in NSCLC, especially Class 2/3 that lack treatment options. #CancerResearch #BRAF #LungCancer
Tuesday, April 29th 2:50 PM CT | @UCSF at #AACR25 | @Tadashi_Manabe @bivonalab presents "Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLCr" ow.ly/A3NL50VJheK
Join the @BivonaLabUCSF team at #AACR25 Chicago on April 29th! @Tadashi_Manabe 2:30-4:00 PM, Minisymposium Room S102 @YTChou 2:00-5:00 PM, Poster Section 18 Nilanjana Chatterjee 2:00-5:00 PM, Poster Section 17 Stop by to discuss our latest research findings! @UCSFCancer @UCSF
Such a pleasure to host and attend HTTR24! Drug resistance in cancer is a fundamental problem limiting cures, but I have so much hope after seeing the new advances emerging from colleagues around the world. Thank you to the speakers and attendees for making this meeting a success
Congratulations to the chairs of the @IASLC #HTTR24 meeting - fantastic faculty and content. Engaging. Amazing faculty list. Hope it becomes a regular occurrence! Amazing job by Drs. @WWL_18 @CespedesMontse @aliceb_phd and Kenichi Suda!
Team @BivonaLabUCSF at Washington DC for #HTTR24 , @IASLC ! @bergo_hannah
I had a wonderful time at #HTTR24 , @IASLC ! Yesterday, I had the opportunity to present our recent work on Exarafenib, a novel therapeutic approach that addresses a critical unmet need in BRAF-mutated lung cancer. Thanks to all the researchers who shared their insights!
Keynote speaker at #HTTR24 Dr. Trever Bivona @BivonaLabUCSF discussing about the mechanisms involved in tolerance and Resistance to Targeted Therapies. Very inspiring talk. @IASLC @JenniferCKing
I'm heading to Boston tomorrow for the 2024 Damon Runyon Fellows Retreat starting on the 15th. Excited to connect with brilliant cancer researchers from across the US and present my research progress! Looking forward to inspiring discussions!
I'm honored to give a lecture at Fukuoka Institute of Technology in Japan on September 20th. I'll be sharing my invaluable experiences in the US under the title "Challenging Cancer Research Globally! My Study Abroad Experience on the Frontlines.”
【セミナー開催】「世界で挑む！がん研究の最前線と私の留学体験談」 9/20(金) 15時〜16時、本学A24教室にて眞鍋維志先生（UCSF）によるセミナーを開催します。福岡工業大学の学生さんで、研究や留学に興味のある方はぜひご参加ください！ 詳細↓ t-akagi-lab.com/post/blog44
Excited to head to Chicago for #ASCO24! Looking forward to connecting with my collaborators and colleagues from Japan. Ready to share insights and drive innovation in cancer research!
Just out @Nature The 1st whole-slide digital pathology #AI foundation model pre-trained on large-scale real-world data, from over 1.3 billion images, 30,000 patients nature.com/articles/s4158… @hoifungpoon @HanwenXu6 @Microsoft @UW @naotous @MSFTResearch
Loved this event! It was such a nice experience meeting new people from both industry and academia. I learned so many things today, and I have to start taking notes before I forget! A huge thank you to the organizers for putting together such a valuable event!!
Today, we're looking forward to gathering our scientists together with industry partners in South San Francisco for the 2024 Accelerating Cancer Cures Symposium, hosted by @AbbVie.
This is why testing for co-mutations is so important. Dr @StockhammerPaul research shows that having 2+ tumor supressor genes in EGFR NSCLC indicates aggressive disease. This may help determine if additional treatment is warranted. Make sure your doctors are testing for this
Excited to share our recent work now published in @JTOonline: 👉Pts with #EGFR mt NSCLC with co-mut in TP53 and another suppressor gene have ⬆️aggressive dz and ⬇️outcomes on TKIs. 👉These findings may help to identify pts for Tx strategies beyond Osi. jto.org/article/S1556-…
With a chemical biology mindset, truly nothing is undruggable. Here, the active state of KRAS via modified Cyclophilin A ligands. Have been looking forward to seeing this in print. Congratulations, RevMed. science.org/doi/10.1126/sc…
We are hiring! Come join us @MSKCancerCenter and study these amazing self-assembling structures that organize RAS signaling and DNA repair! #MSKKids
Postdoctoral Fellow in Pediatric Cancer Research at MSKCC @TulpuleLab Interested in pediatric cancer research? We are hiring postdocs to study biomolecular condensates in cancer. Join us at #MSKCC and #mskkids jobrxiv.org/job/memorial-s… #ScienceJobs...
Today, I had the privilege of lecturing 30 high school students from Japan at UCSF. The topic entailed my practices in Japan and the benefits of conducting research in the U.S. Their vibrant energy invigorated me, and I am thankful to GPI US and UCSF for this great opportunity!
KRAS(G12D) drives lepidic adeno Ca through stem cell reprogramming @Nature by Dr. Nicholas Juul et al. G12D in AT1 cells turns them back into AT2 stem to generate indolent tumor. Possible relationship to the higher % of nonsmokers in G12D! #LCSM @OncoAlert doi.org/10.1038/s41586…